Unicycive Therapeutics Inc Quick Ratio (UNCY) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Unicycive Therapeutics Inc  (NASDAQ: UNCY)

Unicycive Therapeutics Inc's Quick Ratio

UNCY's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 3.28 below Unicycive Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 250 other companies have achieved higher Quick Ratio than Unicycive Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 303 to 1025.

Explain Quick Ratio?
How much Cash & cash equivalents UNCY´s has?
What are UNCY´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

UNCY Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 37.87 % -74.86 % -81.04 % -64.44 % 3.67 %
Y / Y Cash & cash equivalent Change 175.12 % 176.12 % 57.86 % - -
Quick Ratio MRQ 3.28 13.02 9.02 11.48 1.65
UNCY's Total Ranking # 1025 # 303 # 1028 # #
Seq. Current Liabilities Change 346.18 % -8.35 % 22.99 % -72.59 % -18.65 %
Seq. Cash & cash equivalent Change 12.53 % 32.27 % -3.34 % 91.23 % 12.94 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 251
Healthcare Sector # 422
Overall Market # 1025


Quick Ratio Statistics
High Average Low
22.94 5.16 0
(Sep 30 2021)   (Jun 30 2021)




Financial Statements
Unicycive Therapeutics Inc's Current Liabilities $ 19 Millions Visit UNCY's Balance sheet
Unicycive Therapeutics Inc's Cash & cash equivalent $ 61 Millions Visit UNCY's Balance sheet
Source of UNCY's Sales Visit UNCY's Sales by Geography


Cumulative Unicycive Therapeutics Inc's Quick Ratio

UNCY's Quick Ratio for the trailling 12 Months

UNCY Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -51.88 % -59.51 % -50.56 % -1.44 % 1.4 %
Y / Y Cash & cash equivalent TTM Growth 193.06 % 250.41 % 382.21 % 216.04 % 38.01 %
Quick Ratio TTM 6.41 6.18 3.27 1.91 1.05
Total Ranking TTM # 3438 # 3800 # 2712 # #
Seq. Current Liabilities TTM Growth 19.72 % -32.4 % -33.65 % -10.4 % 0.75 %
Seq. Cash & cash equivalent TTM Growth 24.3 % 27.62 % 13.64 % 62.57 % 48.63 %

Quick ratio ranking by company, industry and sector >> Back to UNCY Financial Strength Comparisons >> Go to Compare UNCY Quick Ratio to its Competitors

On the trailing twelve months basis UNCY Cash & cash equivalent more than doubled by 175.12 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Unicycive Therapeutics Inc's Quick Ratio to 6.41, above UNCY average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 449 other companies have achieved higher Quick Ratio than Unicycive Therapeutics Inc. While Quick Ratio overall ranking has improved so far to 3438, from total ranking during the twelve months ending first quarter 2026 at 3800.

Explain Quick Ratio?
How much Cash & cash equivalents UNCY´s has?
What are UNCY´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 450
Healthcare Sector # 918
Within the Market # 3438


trailing twelve months Quick Ratio Statistics
High Average Low
7.23 2.05 0.34
(Jun 30 2022)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Spruce Biosciences Inc   8.78 $ 96.300  Millions$ 10.963  Millions
Newamsterdam Pharma Company N v   8.69 $ 633.854  Millions$ 72.974  Millions
Medicinova Inc   8.58 $ 25.416  Millions$ 2.961  Millions
Lixte Biotechnology Holdings Inc   8.45 $ 12.670  Millions$ 1.500  Millions
Atrium Therapeutics Inc   8.38 $ 264.135  Millions$ 31.508  Millions
Cytomx Therapeutics Inc   8.29 $ 330.280  Millions$ 39.861  Millions
Grace Therapeutics Inc  8.24 $ 13.756  Millions$ 1.669  Millions
Talphera Inc   7.98 $ 33.410  Millions$ 4.188  Millions
Rocket Pharmaceuticals Inc   7.79 $ 342.940  Millions$ 44.031  Millions
Milestone Pharmaceuticals Inc   7.73 $ 171.481  Millions$ 22.184  Millions
Nuvation Bio Inc   7.62 $ 660.956  Millions$ 86.755  Millions
Ibio inc   7.50 $ 88.049  Millions$ 11.745  Millions
Promis Neurosciences inc   7.41 $ 53.463  Millions$ 7.218  Millions
Lakewood-Amedex Biotherapeutics Inc.  7.29 $ 4.585  Millions$ 0.629  Millions
Aspire Biopharma Holdings Inc   7.22 $ 12.167  Millions$ 1.686  Millions
Cartesian Therapeutics Inc   7.18 $ 147.606  Millions$ 20.550  Millions
Kiora Pharmaceuticals Inc   7.10 $ 16.839  Millions$ 2.370  Millions
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions

Date modified: 2026-09-04T00:13:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.